AMR.Solutions

Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused by Gram-negative bacteria “Proposals must target the development of agents for the treatment of Gram-negative priority pathogens” (see our Bugs & Drugs page).

Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in 19 Asian countries during the period Sep 2022 to Feb 2025. Here are the links you need: (the primary paper): Mo Y, Hao X, Ding Y et al. Severe health-care-associated infections and antimicrobial resistance in an Asian Surveillance Network (ACORN-HAI): A multicentre, prospective cohort study.

Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list of funding opportunities: TB! PACCARB! Funding for antifungals! Funding for R&D in India! Look closely! Dear All: The AMR Multi-Stakeholder Partnership Platform (AMR MSPP) collaborated with the Milken Institute on 28 May 2026 to host a 90-minute discussion on innovative models for financing antimicrobial development.

Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public Health.

Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! Here are the details you need: When: 31 Aug 2026 (virtual, 2-4p CET): What: A dialogue on challenges such as fragmented regulatory requirements, trade-offs in clinical trial design, and gaps between evidence generated for regulatory approval and the data needed to inform real-world clinical use and stewardship.

Dear All: Both FDA and EMA have recently released important documents for comment. See below for links and my commentary on the two documents.

Dear All: Two important webinars have just been announced! 22 July (virtual, 2-3.30p CET): The WHO AMR Department and the WHO GAP-r (Global Accelerator for Pediatric Formulations) are hosting an industry dialogue on pediatric and neonatal antibiotic development: The discussion will cover timing of pediatric and neonatal studies, extrapolation from adult data, feasibility of trial designs in children and neonates, and variability in regulatory expectations across jurisdictions.

John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.

Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) is being revived at a 16 June 2026 virtual meeting! Here are the links you need: 19 May 2026 Federal Register notice DHHS webpage about the meeting Date and time: 16 June 2026, 12.30-3.30p ET From the DHHS webpage, we have these notes regarding the meeting: “The 27th PACCARB public meeting will be virtual on June 16, 2026.

John’s Top Recurring Meetings Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers, the small meeting format of BEAM’s AMR Conference (March) and GAMRIC (September-October; formerly, the ESCMID-ASM conference series) creates excellent global networking.